ArticleClinical and experimental vaccine research2024
Clinical presentation, associated factors, and course of cutaneous reaction after the booster dose of COVID-19 vaccination.
Article in Clinical and experimental vaccine research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: A booster coronavirus disease 2019 (COVID-19) vaccination was proposed to preserve immunity and prevent new variants of the severe acute respiratory syndrome coronavirus 2 virus. The objectives of this study are to investigate clinical manifestations, associated factors and course of cutaneous reactions after the booster dose of COVID-19 vaccination, compared to the recommended 1st and 2nd doses. Materials and Methods: This retrospective cohort study was conducted at Siriraj Hospital, Bangkok. Adult patients who reported cutaneous reactions after COVID-19 vaccination from April 2021 to February 2022 were included. Data were collected from electronic medical records and analyzed. Results: A total of 521 subjects with a median age of 38 years were included. Females predominated (80.2%). Most reactions were reported after receiving CoronaVac (49.1%) and ChAdOx1 nCoV-19 (46.3%). The injection site reaction was the most reported. Twenty-one patients reported rash after the 3rd booster dose, with messenger RNA vaccines in most cases. Patients in this group had significantly fewer injection site reactions compared to those with the 1st and 2nd vaccination (70.6% vs. 91.5%) with an increasing proportion of new-onset urticaria (17.6% vs. 5.4%, p=0.023). The rash after the 3rd booster vaccination tended to have a longer duration of reactions (p=0.001). Boosting with a vaccine different from the 1st dose may not affect the reaction. Age and sex did not affect booster rash. In this study, no serious cutaneous reactions were found. Conclusion: Most adverse cutaneous reactions after COVID-19 vaccination are mild in severity, especially after booster vaccination, and should not discourage the benefits of getting vaccinated.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.